Alpa Laboratories Limited (ALPA.BO)
INR 105.3
(1.4%)
INR 105.3
(1.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 188.89 Million INR | -38.9% |
| 2022 | 309.13 Million INR | -10.2% |
| 2021 | 344.26 Million INR | 8.74% |
| 2020 | 316.58 Million INR | 6.93% |
| 2019 | 296.05 Million INR | 26.88% |
| 2018 | 233.32 Million INR | 5.64% |
| 2017 | 220.87 Million INR | -3.64% |
| 2016 | 229.2 Million INR | 0.22% |
| 2015 | 228.7 Million INR | 31.57% |
| 2014 | 173.83 Million INR | -13.35% |
| 2013 | 200.62 Million INR | 27.06% |
| 2012 | 157.9 Million INR | 29.94% |
| 2011 | 121.51 Million INR | 24.16% |
| 2010 | 97.87 Million INR | 8.11% |
| 2009 | 90.52 Million INR | 0.87% |
| 2008 | 89.74 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 25.52 Million INR | -5.1% |
| 2023 Q4 | 67.61 Million INR | -26.5% |
| 2023 Q1 | 37 Million INR | -78.24% |
| 2023 Q2 | 100.75 Million INR | 172.24% |
| 2023 Q3 | 91.99 Million INR | -8.69% |
| 2023 FY | 188.89 Million INR | -38.9% |
| 2022 Q2 | -9.66 Million INR | -116.4% |
| 2022 FY | 309.13 Million INR | -10.2% |
| 2022 Q4 | 170.1 Million INR | 89.53% |
| 2022 Q3 | 89.74 Million INR | 1028.59% |
| 2022 Q1 | 58.94 Million INR | -18.71% |
| 2021 Q3 | 98.46 Million INR | 14.12% |
| 2021 Q4 | 72.5 Million INR | -26.36% |
| 2021 Q2 | 86.28 Million INR | -0.84% |
| 2021 Q1 | 87 Million INR | 48.65% |
| 2021 FY | 344.26 Million INR | 8.74% |
| 2020 Q2 | 67.67 Million INR | 1.68% |
| 2020 Q4 | 58.53 Million INR | -51.07% |
| 2020 Q1 | 66.55 Million INR | -10.43% |
| 2020 FY | 316.58 Million INR | 6.93% |
| 2020 Q3 | 119.61 Million INR | 76.75% |
| 2019 Q3 | 87.17 Million INR | 28.81% |
| 2019 FY | 296.05 Million INR | 26.88% |
| 2019 Q1 | 66.8 Million INR | 113.71% |
| 2019 Q2 | 67.67 Million INR | 1.3% |
| 2019 Q4 | 74.3 Million INR | -14.77% |
| 2018 Q3 | 87.17 Million INR | 55.6% |
| 2018 Q1 | 57.43 Million INR | 0.0% |
| 2018 FY | 233.32 Million INR | 5.64% |
| 2018 Q4 | 31.26 Million INR | -64.14% |
| 2018 Q2 | 56.02 Million INR | -2.45% |
| 2017 FY | 220.87 Million INR | -3.64% |
| 2016 FY | 229.2 Million INR | 0.22% |
| 2015 FY | 228.7 Million INR | 31.57% |
| 2015 Q2 | 89.53 Million INR | 45.62% |
| 2015 Q1 | 61.48 Million INR | 743.75% |
| 2014 Q1 | 48.95 Million INR | 79.83% |
| 2014 Q2 | 58.88 Million INR | 20.28% |
| 2014 Q3 | 58.7 Million INR | -0.31% |
| 2014 Q4 | 7.28 Million INR | -87.59% |
| 2014 FY | 173.83 Million INR | -13.35% |
| 2013 FY | 200.62 Million INR | 27.06% |
| 2013 Q2 | 44.9 Million INR | -14.72% |
| 2013 Q3 | 75.83 Million INR | 68.87% |
| 2013 Q4 | 27.22 Million INR | -64.1% |
| 2013 Q1 | 52.65 Million INR | 79.18% |
| 2012 Q3 | 48.9 Million INR | 25.5% |
| 2012 Q2 | 38.97 Million INR | -6.48% |
| 2012 Q1 | 41.67 Million INR | 271.64% |
| 2012 FY | 157.9 Million INR | 29.94% |
| 2012 Q4 | 29.38 Million INR | -39.91% |
| 2011 Q3 | 37.76 Million INR | 0.0% |
| 2011 Q4 | 11.21 Million INR | -70.31% |
| 2011 FY | 121.51 Million INR | 24.16% |
| 2010 FY | 97.87 Million INR | 8.11% |
| 2009 FY | 90.52 Million INR | 0.87% |
| 2008 FY | 89.74 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 99.295% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.878% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 98.481% |
| Granules India Limited | 16.79 Billion INR | 98.876% |
| Indoco Remedies Limited | 6.04 Billion INR | 96.873% |
| Achyut Healthcare Limited | 4.86 Million INR | -3785.929% |
| Ajanta Pharma Limited | 21.06 Billion INR | 99.103% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.639% |
| Brooks Laboratories Limited | 65.62 Million INR | -187.862% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 96.964% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 87.166% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 94.888% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.885% |
| Eris Lifesciences Limited | 10.42 Billion INR | 98.188% |
| FDC Limited | 8.33 Billion INR | 97.734% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.728% |
| Gufic Biosciences Limited | 4.16 Billion INR | 95.468% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 96.951% |
| Ipca Laboratories Limited | 29.8 Billion INR | 99.366% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 71.055% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | 1.988% |
| Lasa Supergenerics Limited | 121.02 Million INR | -56.073% |
| Laurus Labs Limited | 24.62 Billion INR | 99.233% |
| Lupin Limited | 123.71 Billion INR | 99.847% |
| Mankind Pharma Limited | 44.52 Billion INR | 99.576% |
| Medicamen Biotech Limited | 495.49 Million INR | 61.878% |
| Medico Remedies Limited | 262.14 Million INR | 27.942% |
| Megasoft Limited | 342.07 Million INR | 44.779% |
| NATCO Pharma Limited | 25.73 Billion INR | 99.266% |
| Piramal Pharma Limited | 24.47 Billion INR | 99.228% |
| RPG Life Sciences Limited | 2.48 Billion INR | 92.392% |
| Sigachi Industries Limited | 2 Billion INR | 90.566% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.927% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 95.419% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 79.956% |
| Unichem Laboratories Limited | 4.86 Billion INR | 96.117% |
| Wanbury Limited | 1.73 Billion INR | 89.085% |
| Windlas Biotech Limited | 1.33 Billion INR | 85.891% |
| ZIM Laboratories Limited | 1.26 Billion INR | 85.09% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.849% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 131.357% |
| Divi's Laboratories Limited | 32.44 Billion INR | 99.418% |
| Hester Biosciences Limited | 1.27 Billion INR | 85.169% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 96.733% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 87.864% |
| Bal Pharma Limited | 770.19 Million INR | 75.474% |
| Strides Pharma Science Limited | 14.38 Billion INR | 98.687% |
| Venus Remedies Limited | 2.18 Billion INR | 91.345% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 96.761% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 93.644% |
| Shilpa Medicare Limited | 3.54 Billion INR | 94.674% |
| Aarti Drugs Limited | 8.31 Billion INR | 97.729% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 95.876% |
| Suven Life Sciences Limited | -200.79 Million INR | 194.073% |
| Ind-Swift Limited | 2.17 Billion INR | 91.305% |
| Valiant Laboratories Limited | -60.66 Million INR | 411.379% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 99.168% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 78.066% |
| Themis Medicare Limited | 1.5 Billion INR | 87.44% |
| Hikal Limited | 3.14 Billion INR | 93.99% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.596% |
| Sequent Scientific Limited | 2.97 Billion INR | 93.659% |
| Novartis India Limited | 1.32 Billion INR | 85.764% |
| Wockhardt Limited | 16.24 Billion INR | 98.837% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 99.038% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -1195.603% |
| Neuland Laboratories Limited | 8.24 Billion INR | 97.71% |
| Morepen Laboratories Limited | 6.16 Billion INR | 96.934% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 69.556% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | 73.153% |